**JPED-D-21-00114 – Supplemental Material**

**Supplemental Table 1 - Baseline characteristics of included studies for qualitative synthesis.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Author, Year** | **No. of cases** | **Age (y)** | **Dex dose/ Administration** |
| Prasad et al. 2012[36] | 30 | 6.07 ± 3.94 | SBP, DBP, HR |
| Potts et al. 2010[37] | 29 | 2.67 (4d-14y) | MAP |
| Hasegawa et al. 2015[38] | 20 | 0.23 ± 0.21 | HR, CVP, SBP |
| Tokuhira et al. 2009[39] | 9 | 1.30 ± 2.50 | MAP, CVP, HR |
| Hosokawa et al. 2010[40] | 56 | 1.00 ± 1.78 | Classified data |
| Totonchi et al. 2017[41] | 20 | 1.30 ± 9.10 | HR, CVP, SBP |
| Klamt et al. 2010[42] | 14 | 0.90 ± 1.80 | HR, SBP, DBP |
| Bejian et al. 2009[43] | 54 | 0.50 (1d-16y) | MAP, HR |
| Barton et al. 2008[44] | 6 | 0.53 (3d-2.4y) | SBP, HR |

Age show in mean ± SD or median (range).

Dex, dexmedetomidine; mo, month; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; CVP, central venous pressure.